Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

DC FieldValueLanguage
dc.contributor.authorMartin, William P.-
dc.contributor.authorWhite, James-
dc.contributor.authorLópez-Hernández, Francisco J.-
dc.contributor.authorDocherty, Neil G.-
dc.contributor.authorle Roux, Carel W.-
dc.date.accessioned2021-11-29T11:20:33Z-
dc.date.available2021-11-29T11:20:33Z-
dc.date.copyright2020 the Authorsen_US
dc.date.issued2020-08-17-
dc.identifier.citationFrontiers in Endocrinologyen_US
dc.identifier.issn1664-2392-
dc.identifier.urihttp://hdl.handle.net/10197/12672-
dc.description.abstractObesity is a major factor in contemporary clinical practice in nephrology. Obesity accelerates the progression of both diabetic and non-diabetic chronic kidney disease and, in renal transplantation, both recipient and donor obesity increase the risk of allograft complications. Obesity is thus a major driver of renal disease progression and a barrier to deceased and living donor kidney transplantation. Large observational studies have highlighted that metabolic surgery reduces the incidence of albuminuria, slows chronic kidney disease progression, and reduces the incidence of end-stage kidney disease over extended follow-up in people with and without type 2 diabetes. The surgical treatment of obesity and its metabolic sequelae has therefore the potential to improve management of diabetic and non-diabetic chronic kidney disease and aid in the slowing of renal decline toward end-stage kidney disease. In the context of patients with end-stage kidney disease, although complications of metabolic surgery are higher, absolute event rates are low and it remains a safe intervention in this population. Pre-transplant metabolic surgery increases access to kidney transplantation in people with obesity and end-stage kidney disease. Metabolic surgery also improves management of metabolic complications post-kidney transplantation, including new-onset diabetes. Procedure selection may be critical to mitigate the risks of oxalate nephropathy and disruption to immunosuppressant pharmacokinetics. Metabolic surgery may also have a role in the treatment of donor obesity, which could increase the living kidney donor pool with potential downstream impact on kidney paired exchange programmes. The present paper provides a comprehensive coverage of the literature concerning renal outcomes in clinical studies of metabolic surgery and integrates findings from relevant mechanistic pre-clinical studies. In so doing the key unanswered questions for the field are brought to the fore for discussion.en_US
dc.description.sponsorshipHealth Research Boarden_US
dc.description.sponsorshipHealth Service Executiveen_US
dc.description.sponsorshipScience Foundation Irelanden_US
dc.description.sponsorshipWellcome Trusten_US
dc.format.mediumElectronic-eCollection-
dc.language.isoenen_US
dc.publisherFrontiersen_US
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.subjectRenal transplantationen_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectDiabetic kidney diseaseen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectEnd-stage kidney diseaseen_US
dc.subjectKidney transplantationen_US
dc.subjectDialysisen_US
dc.subjectLaproscopic sleeve gastrectomyen_US
dc.subjectY-gastric bypassen_US
dc.subjectIntensive medical therapyen_US
dc.titleMetabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?en_US
dc.typeJournal Articleen_US
dc.internal.authorcontactotherwilliam.martin@ucd.ieen_US
dc.statusPeer revieweden_US
dc.identifier.volume11en_US
dc.citation.otherArticle Number: 289en_US
dc.identifier.doi10.3389/fendo.2020.00289-
dc.neeo.contributorMartin|William P.|aut|-
dc.neeo.contributorWhite|James|aut|-
dc.neeo.contributorLópez-Hernández|Francisco J.|aut|-
dc.neeo.contributorDocherty|Neil G.|aut|-
dc.neeo.contributorle Roux|Carel W.|aut|-
dc.description.othersponsorshipSwedish Medical Research Councilen_US
dc.description.othersponsorshipEuropean Foundation for the Study of Diabetesen_US
dc.date.updated2020-10-20T19:56:20Z-
dc.identifier.grantid203930/B/16/Z-
dc.identifier.grantid12/YI/B2480-
dc.identifier.grantid2015-02733-
dc.identifier.grantidBI 2017_3-
dc.rights.licensehttps://creativecommons.org/licenses/by/3.0/ie/en_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Conway Institute Research Collection
Medicine Research Collection
Files in This Item:
 File SizeFormat
Downloadfendo-11-00289.pdf3.15 MBAdobe PDF
Show simple item record

Page view(s)

353
Last Week
2
Last month
28
checked on May 18, 2022

Download(s)

18
checked on May 18, 2022

Google ScholarTM

Check

Altmetric


If you are a publisher or author and have copyright concerns for any item, please email research.repository@ucd.ie and the item will be withdrawn immediately. The author or person responsible for depositing the article will be contacted within one business day.